HBAN vs NKTR · P/E 13, rev $1.56B vs rev $21.0M
Huntington Bancshares Incorporated (HBAN) versus Nektar Therapeutics (NKTR) — a side-by-side from cached financials, not a winner call.
Huntington Bancshares Incorporated (HBAN) is a banks - regional company listed on US.
Nektar Therapeutics (NKTR) is a biotechnology company listed on US.
Latest reported HBAN revenue for 2025-12-31 was $1.56B. Net income was $2.21B. Revenue was up 6.4% from 2024-12-31 to 2025-12-31. HBAN currently screens at market cap $25.55B and trailing P/E 13.5.
Latest reported NKTR revenue for 2026-06-30 was $21.0M. Net income was -$85.5M. Revenue was up 93.3% from 2026-03-31 to 2026-06-30. NKTR currently screens at market cap $307.2M.
HBAN currently screens at market cap $25.55B and trailing P/E 13.5. NKTR currently screens at market cap $307.2M.
Not investment advice. Open the HBAN and NKTR stock pages for the full models.
Not investment advice.